Orgenesis to Present Today at the Winter Wonderland Conference-Best Ideas from the Buy-Side
February 16 2021 - 7:00AM
Orgenesis Inc. (NASDAQ: ORGS)
(“Orgenesis” or the “Company”), a global biotech company working to
unlock the full potential of cell and gene therapies, today
announced that it will be presenting at the Winter Wonderland
Conference, hosted by The MicroCap Rodeo, being held virtually on
February 16th - February 19th, 2021.
Vered Caplan, CEO of Orgenesis, is scheduled to present today,
February 16th, 2021 at 2:30 PM, Eastern Time. The presentation will
be webcast live and available for replay here. One-on-one meetings
will be held throughout the conference via video conference
calls.
About the Winter Wonderland
ConferenceThe MicroCap Rodeo is hosting its “Winter
Wonderland Conference- Best Ideas Bowl,” with 25-minute virtual
presentations from the 16th to 17th, and one-on-ones for qualified
institutional investors on the 18th and 19th. This conference is a
virtual conference that brings you the top 25 best ideas from the
buy side. Qualified institutional investors recommended each of the
25 companies represented as one of their best ideas. For more
information, please visit the event website:
https://microcaprodeo.com/.
About OrgenesisOrgenesis is a global biotech
company working to unlock the full potential of cell and gene
therapies (CGTs) in an affordable and accessible format at the
point of care. The Orgenesis POCare Platform
is comprised of three enabling components: a pipeline of
licensed POCare Therapeutics that are
processed and produced in closed, automated POCare
Technology systems across a
collaborative POCare Network.
Orgenesis identifies promising new therapies and leverages its
POCare Platform to provide a rapid, globally harmonized pathway for
these therapies to reach and treat large numbers of patients at
lowered costs through efficient, scalable, and decentralized
production. The POCare Network brings together patients, doctors,
industry partners, research institutes and hospitals worldwide to
achieve harmonized, regulated clinical development and production
of the therapies. Learn more about the work Orgenesis is doing
at www.orgenesis.com.
Contact for Orgenesis:David WaldmanCrescendo
Communications, LLCTel: 212-671-1021
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Apr 2023 to Apr 2024